Related Experiment Videos
Massive blood transfusion in the elective surgical setting.
1Department of Haematology, Western Australian Centre for Pathology, Nedlands. wendy.erber@health.wa.gov.au
Summary
Managing massive hemorrhage in surgery requires prompt recognition, hemostasis, and normovolemia. Blood product support, guided by lab tests, is crucial, with alternatives for uncontrollable bleeding to minimize complications.
Area of Science:
- Anesthesiology
- Hematology
- Surgical Sciences
Background:
- Massive hemorrhage during elective surgery presents anticipated or unexpected challenges.
- Effective management hinges on early recognition, achieving hemostasis, and maintaining normovolemia.
Purpose of the Study:
- To outline the principles and practices for managing massive hemorrhage in elective surgery.
- To discuss blood product transfusion strategies and alternative treatments.
- To highlight potential complications and mitigation strategies associated with massive transfusion.
Main Methods:
- Review of current transfusion management protocols for massive hemorrhage.
- Emphasis on clinical judgment combined with laboratory coagulation tests.
- Consideration of alternative blood products and pharmacological agents when hemostasis is difficult.
Main Results:
- Critical laboratory thresholds (e.g., PT/aPTT >1.8, fibrinogen <1.0 g/l, platelets <80 x 10(9)/l) indicate difficulty in achieving hemostasis.
- Uncontrollable hemorrhage may necessitate alternative strategies beyond standard blood component therapy.
- Complications of massive transfusion include storage lesions, DIC, hypothermia, and hypovolemic shock.
Conclusions:
- Optimal management of massive hemorrhage involves timely recognition, hemostasis, and normovolemia.
- Blood product support should be guided by clinical assessment and laboratory data.
- Utilizing fresh blood products and leucocyte-reduced components may reduce adverse outcomes.